AbbVie (ABBV.US) JAK inhibitor "upadacitinib" is proposed for priority review in China.

On December 10, the official website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration announced that AbbVie (ABBV.US) has applied for the inclusion of upadacitinib sustained-release tablets in priority review, with the intended indication being the treatment of adult giant cell arteritis (GCA).

Zhitong Finance10:03

BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $191

Futu News16:32 · Ratings

Bank of America has resumed coverage of AbbVie with a "neutral" rating.

Gelonghui, December 11 | Bank of America: Resumed coverage of AbbVie, giving it a 'Neutral' rating, with a Target Price of $191. (Gelonghui)

Gelonghui Finance16:09

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking Alpha06:01

Analyst Scoreboard: 19 Ratings For AbbVie

BenzingaDec 10 21:02

B of A Securities Reinstates Neutral on AbbVie, Announces $191 Price Target

BenzingaDec 10 20:37 · Ratings